Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of IBI311 in inactive thyroid eye disease
CTR20252912Phase 3Active
- Sponsor
- InnoCare Pharma
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of sycume in Graves Orbitopathy (GO), sponsored by InnoCare Pharma. Started Sep 2025; status: active.
02
Drugs
sycume
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on CTR20252912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252912.